Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Antiretroviral combination therapy in HIV-1 infected women and men: are their responses different?
Int J Fertil Womens Med. 2000 Mar-Apr;45(2):195-9. Unique Identifier : AIDSLINE MED/20290036 Zorrilla CD; Department of Obstetrics and Gynecology, University of Puerto; Rico, School of Medicine, San Juan 00936-5067, USA.
Abstract:
Women are the fastest growing segment of the AIDS cases in the United States. They constitute nearly half of all the AIDS cases worldwide. Recent advances in Highly Active Antiretroviral Therapies (HAART) have reduced AIDS mortality remarkably. But as longer use of these combination regimens makes evident, unexpected side effects are now reported that might reflect gender-based differences in occurrence. Controversy still exists in relation to the level of HIV-1 quantification in men and women and its association with disease progression. Women have been reported to have lower viral loads with equal progression or higher progression with equal viral loads. This finding has not been consistent in all studies. Psychosocial variables, such as poverty, lack of care and young age, adversely affect more women than men. If the viral dynamics are thought to be different, then the response to treatment might be as well. So far, the effectiveness of HAART has been seen equally among men and women. Barriers to adherence, such as caregiving burdens, multiplicity of roles and fear of disclosure, might disproportionately affect women. By far the best news is that the survival of both men and women has improved with the newer therapeutic advances.
Keywords: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Acquired Immunodeficiency Syndrome/DRUG THERAPY/MORTALITY Adolescence Adult Anti-HIV Agents/*ADMINISTRATION & DOSAGE Comparative Study Drug Therapy, Combination Female Human HIV Infections/*DRUG THERAPY/MORTALITY/VIROLOGY HIV-1/*DRUG EFFECTS Male Middle Age Prognosis Risk Assessment Sex Factors Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Survival Analysis Treatment Outcome Viral Load 001030
A00A1082
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from
Elton John AIDS Foundation,
the National Library of Medicine,
and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
